Efficacy and safety of tyrosine kinase inhibitors in the treatment of HER2-positive breast cancer:a meta-analysis
OBJECTIVE To evaluate the efficacy and safety of tyrosine kinase inhibitors(TKI)in the treatment of HER2-positive breast cancer in order to provide evidence-based evidence for clinical medication.METHODS Retrieved from CNKI,Wanfang database,VIP,PubMed,Cochrane Library,Embase and Web of Science,randomized controlled trial(RCT)about TKI(trial group)versus drugs excluding TKI(control group)in the treatment of HER2-positive breast cancer were collected from the establishment of the database to April 2023.Meta-analysis and sensitivity analysis were performed by using RevMan 5.4.1 and Stata 17 software.RESULTS Total of 24 RCT studies were included,involving 15 538 HER2-positive breast cancer patients.The meta-analysis results showed that compared with the control group,the progression-free survival(PFS)[HR=0.91,95%CI(0.80,1.02),P=0.12],overall survival(OS)[HR=0.95,95%CI(0.89,1.01),P=0.11],objective response rate(ORR)[OR=1.21,95%CI(0.86,1.69),P=0.27],and pathological complete response rate(pCR)[OR=1.44,95%CI(0.91,2.27),P=0.12]had no statistically significant difference in the trial group;among the 3/4 grade ADRs,the trial group had a higher incidence of anemia[OR=1.77,95%CI(1.16,2.70),P=0.008],rash[OR=11.26,95%CI(7.32,17.31),P＜0.000 01],paronychia[OR=8.67,95%CI(1.62,46.53),P=0.01],diarrhea[OR=10.17,95%CI(5.03,20.58),P＜0.000 01],oral mucositis inflammation[OR=9.34,95%CI(3.13,27.83),P＜0.000 1],elevated aspartate aminotransferase[OR=2.09,95%CI(1.13,3.84),P=0.02],and hypokalemia[OR=2.37,95%CI(1.31,4.30),P=0.005]than that of the control group.Subgroup analysis results showed that compared with the placebo group,TKI could improve OS and ORR(P＜0.05),while compared with trastuzumab,TKI had no advantage in PFS,OS,ORR,and pCR,and TKI combined with trastuzumab could significantly improve PFS,OS,ORR,and pCR compared with the trastuzumab group(P＜0.05).Sensitivity analysis suggested that the results were relatively robust and the risk of publication bias was low.CONCLUSIONS Compared with trastuzumab,TKI has no advantages in PFS,OS,ORR and pCR in the treatment of HER2-positive breast cancer,but TKI combined with trastuzumab can significantly improve PFS,OS,ORR and pCR;TKI can increase the risk of grade 3/4 anemia,rash,paronychia,diarrhea,oral mucositis,elevated aspartate aminotransferase,and hypokalemia.
tyrosine kinase inhibitorHER2-positive breast cancerefficacysafety
万方数据
维普
